PSMA-targeted [18F]DCFPyL PET/CT-avid lesions in a patient with prostate cancer

Clinical decision-making informed by the PSMA-RADS interpretive framework

Research output: Contribution to journalArticle

Abstract

We present the case of a man with oligometastatic prostate cancer who underwent a PSMA-targeted 18F-DCFPyL PET/CT scan in order to illustrate how the PSMA-RADS grading sytem can be successfully used to support clinical decision-making and treatment planning. Notably, the presented patient was found to have an equivocal bone lesion (PSMA-RADS-3B) which was further worked up with a tumor protocol MRI and found to be definitively benign (PSMA-RADS-1B) and thus removed from the oligometastatic treatment plan. Remaining avid lesions were incorporated into the treatment plan or deferred for later work-up or monitoring, as indicated within the PSMA-RADS framework.

Original languageEnglish (US)
Pages (from-to)72-74
Number of pages3
JournalUrology Case Reports
Volume23
DOIs
StatePublished - Mar 1 2019

Fingerprint

Prostatic Neoplasms
Therapeutics
Bone and Bones
Clinical Decision-Making
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
Neoplasms
Positron Emission Tomography Computed Tomography

Keywords

  • DCFPyL
  • Oligometastatic
  • Prostate cancer
  • PSMA

ASJC Scopus subject areas

  • Urology

Cite this

@article{779b46f83e874648aed667baf8bffeba,
title = "PSMA-targeted [18F]DCFPyL PET/CT-avid lesions in a patient with prostate cancer: Clinical decision-making informed by the PSMA-RADS interpretive framework",
abstract = "We present the case of a man with oligometastatic prostate cancer who underwent a PSMA-targeted 18F-DCFPyL PET/CT scan in order to illustrate how the PSMA-RADS grading sytem can be successfully used to support clinical decision-making and treatment planning. Notably, the presented patient was found to have an equivocal bone lesion (PSMA-RADS-3B) which was further worked up with a tumor protocol MRI and found to be definitively benign (PSMA-RADS-1B) and thus removed from the oligometastatic treatment plan. Remaining avid lesions were incorporated into the treatment plan or deferred for later work-up or monitoring, as indicated within the PSMA-RADS framework.",
keywords = "DCFPyL, Oligometastatic, Prostate cancer, PSMA",
author = "Reyes, {Diane K.} and Shadpour Demehri and Werner, {Rudolf A.} and Pomper, {Martin Gilbert} and Michael Gorin and Steven Rowe and Kenneth Pienta",
year = "2019",
month = "3",
day = "1",
doi = "10.1016/j.eucr.2019.01.007",
language = "English (US)",
volume = "23",
pages = "72--74",
journal = "Urology Case Reports",
issn = "2214-4420",
publisher = "Elsevier Saunders",

}

TY - JOUR

T1 - PSMA-targeted [18F]DCFPyL PET/CT-avid lesions in a patient with prostate cancer

T2 - Clinical decision-making informed by the PSMA-RADS interpretive framework

AU - Reyes, Diane K.

AU - Demehri, Shadpour

AU - Werner, Rudolf A.

AU - Pomper, Martin Gilbert

AU - Gorin, Michael

AU - Rowe, Steven

AU - Pienta, Kenneth

PY - 2019/3/1

Y1 - 2019/3/1

N2 - We present the case of a man with oligometastatic prostate cancer who underwent a PSMA-targeted 18F-DCFPyL PET/CT scan in order to illustrate how the PSMA-RADS grading sytem can be successfully used to support clinical decision-making and treatment planning. Notably, the presented patient was found to have an equivocal bone lesion (PSMA-RADS-3B) which was further worked up with a tumor protocol MRI and found to be definitively benign (PSMA-RADS-1B) and thus removed from the oligometastatic treatment plan. Remaining avid lesions were incorporated into the treatment plan or deferred for later work-up or monitoring, as indicated within the PSMA-RADS framework.

AB - We present the case of a man with oligometastatic prostate cancer who underwent a PSMA-targeted 18F-DCFPyL PET/CT scan in order to illustrate how the PSMA-RADS grading sytem can be successfully used to support clinical decision-making and treatment planning. Notably, the presented patient was found to have an equivocal bone lesion (PSMA-RADS-3B) which was further worked up with a tumor protocol MRI and found to be definitively benign (PSMA-RADS-1B) and thus removed from the oligometastatic treatment plan. Remaining avid lesions were incorporated into the treatment plan or deferred for later work-up or monitoring, as indicated within the PSMA-RADS framework.

KW - DCFPyL

KW - Oligometastatic

KW - Prostate cancer

KW - PSMA

UR - http://www.scopus.com/inward/record.url?scp=85060340100&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060340100&partnerID=8YFLogxK

U2 - 10.1016/j.eucr.2019.01.007

DO - 10.1016/j.eucr.2019.01.007

M3 - Article

VL - 23

SP - 72

EP - 74

JO - Urology Case Reports

JF - Urology Case Reports

SN - 2214-4420

ER -